A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma Academic Article uri icon

Overview

MeSH Major

  • Lymphoma
  • Multiple Myeloma
  • Oligopeptides
  • Proteasome Inhibitors

abstract

  • Escalated dosing of carfilzomib on a schedule of 2 consecutive days for 3 weeks of a 4-week cycle was tolerable and showed promising activity. This dose regimen has been selected for ongoing and future clinical studies, including PX-171-003A1 and the pivotal trial ASPIRE.

publication date

  • September 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-11-3007

PubMed ID

  • 22761464

Additional Document Info

start page

  • 4830

end page

  • 40

volume

  • 18

number

  • 17